Can-Fite BioPharma Ltd. CANF 深 沪
等待开盘 02-02 09:30:00 美东时间
4.01
-0.090
-2.20%
华盛通- 最 高4.18
- 今 开4.00
- 成交量 1.90万股
- 最 低 4.00
- 昨 收 4.10
- 总市值 342.29万
- 52周最高 46.60
- 市盈率 静 --
- 换手率 2.23%
- 52周最低 3.356
- 委 比 33.33%
- 总股本 85.36万
- 历史最高 28380.00
- 量 比 0.45
- 振 幅 4.39%
- 历史最低 3.356
- 每 手 1
- 风险率 9.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson
Can-Fite BioPharma Ltd. announces completion of patient enrollment in its Phase 2a pancreatic cancer clinical trial for Namodenoson, a selective A3 adenosine receptor agonist. The trial evaluates safety, clinical activity, and pharmacokinetics in advanced pancreatic adenocarcinoma patients. Namodenoson has shown a favorable safety profile, and top-line efficacy data is expected in Q3 2026. The drug has received Orphan Drug Designation from the FD...
01-20 12:00
Can-Fite BioPharma Discloses Resignation of Director Yaacov Goldman
The latest update is out from Can-Fite BioPharma ( ($CANF) ). On January 14, 20...
01-17 05:47
Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction
Can-Fite BioPharma Ltd. has received Patent No. BR112015002697-4 from the Brazilian Patent Office for using its proprietary A3 adenosine receptor agonists to treat sexual dysfunction. This strengthens its global patent portfolio and taps into Brazil's large pharmaceutical market. Preclinical and clinical data suggest A3AR activation may improve erectile and sexual function. The patent supports Can-Fite's therapeutic strategy and opens opportuniti...
2025-12-26 12:00
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Indaptus Therapeutics (NASDAQ:INDP) stock rose 63.6% to $3.19 during W...
2025-12-24 20:05
UiPath, Ramaco Resources And 3 Stocks To Watch Heading Into Wednesday
U.S. stock futures slightly lower. UiPath joins S&P Midcap 400, Agios receives FDA approval, Can Fite Biopharma announces reverse split.
2025-12-24 13:07
Can-Fite BioPharma Announces 1-For-3,000 Reverse Share Split, Effective January 5, 2026
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory diseases, announced today that following the
2025-12-24 05:49
Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change
Can-Fite BioPharma Ltd. announced it has approved a 1-for-3,000 reverse split of its ordinary shares, effective on January 5, 2026. Each 3,000 pre-split shares will combine into 1 new share, reducing the total outstanding shares. The ratio of ADSs to ordinary shares will change from 1 ADS representing 300 shares to 1 ADS representing 2 shares. The ADS price is expected to increase proportionally. No fractional shares will be issued; fractional sh...
2025-12-23 21:46
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
2025-12-18 10:54
D. Boral Capital Maintains Buy on Can Fite Biofarma, Lowers Price Target to $4
D. Boral Capital analyst Jason Kolbert maintains Can Fite Biofarma (AMEX:CANF) with a Buy and lowers the price target from $11 to $4.
2025-12-17 20:42
Can-Fite BioPharma Updates on Clinical Trials and Financials
Can-Fite BioPharma ( ($CANF) ) has provided an update. On December 16, 2025, Ca...
2025-12-16 22:58
